# US 2021/0340543 A1 · Non-coding immunomodulatory dna construct

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340543 A1
- Document ID: US20210340543A1
- Status: Published application
- Kind: A1
- Application number: 17/018,088
- Filed: 2020-09-11
- Published: 2021-11-04
- Earliest claimed: 2010-12-23
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Matthias SCHROFF; Christiane KLEUSS; Kerstin KAPP
- Web page: https://patentgrep.com/patent/US20210340543A1

## CPC

- C12N 15/117: Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0011: {Cancer antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 2310/17: Immunomodulatory nucleic acids
- C12N 2310/315: Phosphorothioates
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a nucleic acid molecule and its use for the modulation of the immune system. It provides a DNA construct for immunomodulation comprising at least one nucleotide in L-conformation.

## Claims

### Claim 1

A non-coding, linear open-chained DNA construct without a phosphorothioate backbone for immunomodulation, wherein the DNA construct consists of nucleotides comprising D-DNA and at least one L-DNA nucleotide, wherein said DNA construct comprises at least one sequence motif N1N2CGN3N4 and is a TLR9 agonist, wherein:
the N1N2 is selected from the group consisting of GT, GG, GA, AT or AA, the N3N4 is selected from the group consisting of CT or TT;
C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine, and T is deoxythymidine; and
wherein said at least one L-DNA nucleotide is located in the segment of the DNA construct consisting of five nucleotides at either the 3′-end or the 5′-end or at both the 5′- and the 3′-end of the DNA construct.

### Claim 2 (depends on 1)

The construct according to claim 1, further comprising at least one G stretch comprising three consecutive deoxyguanosines located near the 5′ end or the 3′ end or near both ends of the DNA construct.

### Claim 3 (depends on 1)

The construct according to claim 1, wherein:
said construct comprises at least two of the at least one sequence motifs N1N2CGN3N4; and
said construct further comprises a G stretch comprising three consecutive deoxyguanosines located between two of said at least two sequence motifs N1N2CGN3N4.

### Claim 4 (depends on 1)

The construct according to claim 1, wherein:
said construct comprises at least two of the at least one sequence motifs N1N2CGN3N4; and
said construct further comprises at least five nucleotides selected from the group consisting of C, T and A wherein the at least five nucleotides are located between two of said at least two sequence motifs N1N2CGN3N4.

### Claim 5 (depends on 1)

The construct according to claim 1, wherein the construct comprises single-stranded or double-stranded DNA.

### Claim 6 (depends on 1)

The construct according to claim 1, wherein said at least one sequence motif N1N2CGN3N4 is located within a single-stranded or a double-stranded region or within both regions of the DNA construct.

### Claim 7 (depends on 1)

A composition comprising the construct of claim 1 and further comprising at least two additional DNA constructs, wherein the at least two additional DNA constructs ligate to one another.

### Claim 8 (depends on 1)

The construct according to claim 1, wherein one of said nucleotides comprising D-DNA or the at least one L-DNA nucleotide is modified with a functional group selected from the group consisting of carboxyl, amine, amide, aldimine, ketal, acetal, ester, ether, disulfide, thiol, and aldehyde.

### Claim 9 (depends on 8)

The construct according to claim 8, wherein the at least one modified nucleotide is linked to a compound selected from the group consisting of peptides, proteins, carbohydrates, antibodies, lipids, micelles, vesicles, synthetic molecules, polymers, micro projectiles, metal particles, nanoparticles, and a solid phase.

### Claim 10

A non-coding, linear open-chained DNA construct without a phosphorothioate backbone for immunomodulation, wherein the DNA construct consists of nucleotides comprising D-DNA and at least one L-DNA nucleotide, wherein said DNA construct comprises at least three sequence motifs N1N2CGN3N4 and is a TLR9 agonist, wherein:
N is a nucleotide selected from the group consisting of A, C, T, and G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine, and T is deoxythymidine;
a first G stretch is present at the 5′ end;
the construct further comprises at least five nucleotides selected from the group consisting of C, T and A wherein the at least five nucleotides are located between a first and a second of said at least three sequence motifs;
said construct further comprises a second G stretch, which is located between a second and a third of said at least three sequence motifs; and
two of three 3′ terminal nucleotides are in L-conformation.

### Claim 11 (depends on 10)

The construct according to claim 10, further comprising at least one additional G stretch.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising a DNA construct according to claim 1.

### Claim 13 (depends on 12)

The pharmaceutical composition according to claim 12, further comprising a chemotherapeutic.

### Claim 14

A vaccine comprising a non-coding, linear open-chained DNA construct without a phosphorothioate backbone for immunomodulation, wherein the DNA construct consists of nucleotides comprising D-DNA and at least one L-DNA nucleotide, wherein said DNA construct comprises at least one sequence motif N1N2CGN3N4, wherein N is a nucleotide selected from the group consisting of A, C, T, and G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxythymidine, and wherein said at least one L-DNA nucleotide is located in the segment of the DNA construct consisting of five nucleotides at either the 3′-end or the 5′-end or at both the 5′- and the 3′-end of the DNA construct.

### Claim 15 (depends on 14)

The vaccine according to claim 14, wherein the DNA construct is an adjuvant.

### Claim 16 (depends on 1)

A method of treating cancer or an autoimmune disease, comprising administering the DNA construct according to claim 1.

### Claim 17 (depends on 1)

A method of modulating the immune system, comprising administering the DNA construct according to claim 1.

### Claim 18 (depends on 14)

The vaccine according to claim 14, wherein the N1N2 in the at least one sequence motif of the DNA construct is selected from the group consisting of GT, GG, GA, AT or AA, and the N3N4 of the at least one sequence motif is selected from the group consisting of CT or TT.

### Claim 19 (depends on 18)

The vaccine according to claim 18, wherein the DNA construct is an adjuvant.
